These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34445144)

  • 21. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
    Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
    Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developmental and epileptic encephalopathies: recognition and approaches to care.
    Raga S; Specchio N; Rheims S; Wilmshurst JM
    Epileptic Disord; 2021 Feb; 23(1):40-52. PubMed ID: 33632673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic advances in Dravet syndrome: a targeted literature review.
    Strzelczyk A; Schubert-Bast S
    Expert Rev Neurother; 2020 Oct; 20(10):1065-1079. PubMed ID: 32799683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted gene panel sequencing in early infantile onset developmental and epileptic encephalopathy.
    Na JH; Shin S; Yang D; Kim B; Kim HD; Kim S; Lee JS; Choi JR; Lee ST; Kang HC
    Brain Dev; 2020 Jun; 42(6):438-448. PubMed ID: 32139178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome.
    Polster T
    Epilepsy Behav; 2019 Feb; 91():99-102. PubMed ID: 30269941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies.
    Sullivan J; Simmons R
    Drugs Today (Barc); 2021 Jul; 57(7):449-454. PubMed ID: 34268532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current understanding and neurobiology of epileptic encephalopathies.
    Auvin S; Cilio MR; Vezzani A
    Neurobiol Dis; 2016 Aug; 92(Pt A):72-89. PubMed ID: 26992889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for GRIN2A and GRIN2D-related epileptic encephalopathy.
    Hausman-Kedem M; Menascu S; Greenstein Y; Fattal-Valevski A
    Epilepsy Res; 2020 Jul; 163():106325. PubMed ID: 32289570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
    Zhang L; Li W; Wang C
    Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fenfluramine as antiseizure medication for epilepsy.
    Gogou M; Cross JH
    Dev Med Child Neurol; 2021 Aug; 63(8):899-907. PubMed ID: 33565102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.
    Malar DS; Thitilertdecha P; Ruckvongacheep KS; Brimson S; Tencomnao T; Brimson JM
    CNS Drugs; 2023 May; 37(5):399-440. PubMed ID: 37166702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: A systematic review and meta-analysis.
    Sharawat IK; Panda PK; Kasinathan A; Panda P; Dawman L; Joshi K
    Seizure; 2021 Feb; 85():119-126. PubMed ID: 33461030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study.
    Poisson K; Wong M; Lee C; Cilio MR
    Eur J Paediatr Neurol; 2020 Mar; 25():77-81. PubMed ID: 31926846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The activity of selective sigma-1 receptor ligands in seizure models in vivo.
    Vavers E; Svalbe B; Lauberte L; Stonans I; Misane I; Dambrova M; Zvejniece L
    Behav Brain Res; 2017 Jun; 328():13-18. PubMed ID: 28389336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fenfluramine: A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy.
    Samanta D
    Children (Basel); 2022 Aug; 9(8):. PubMed ID: 36010049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Genetically determined epileptic encephalopathies].
    Appendino JP; Appendino JI
    Medicina (B Aires); 2019; 79 Suppl 3():42-47. PubMed ID: 31603843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients.
    Caraballo RH; Pociecha J; Reyes G; Espeche A; Galichio S; Fasulo L; Semprino M
    Epilepsy Behav; 2020 Jul; 108():107074. PubMed ID: 32334364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reintroducing Fenfluramine as a Treatment for Seizures: Current Knowledge, Recommendations and Gaps in Understanding.
    Dini G; Di Cara G; Ferrara P; Striano P; Verrotti A
    Neuropsychiatr Dis Treat; 2023; 19():2013-2025. PubMed ID: 37790801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural History Studies and Clinical Trial Readiness for Genetic Developmental and Epileptic Encephalopathies.
    Palmer EE; Howell K; Scheffer IE
    Neurotherapeutics; 2021 Jul; 18(3):1432-1444. PubMed ID: 34708325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epileptic encephalopathies].
    Ramos-Lizana J
    Rev Neurol; 2017 May; 64(s03):S45-S48. PubMed ID: 28524219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.